TITLE

The natural history of Noonan syndrome: a long-term follow-up study

AUTHOR(S)
Shaw, A. C.; Kalidas, K.; Crosby, A. H.; Jeffery, S.; Patton, M. A.
PUB. DATE
February 2007
SOURCE
Archives of Disease in Childhood;Feb2007, Vol. 92 Issue 2, p128
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To define better the adult phenotype and natural history of Noonan syndrome. Design: A prospective observational study of a large cohort. Results: Data are presented for 112 individuals with Noonan syndrome (mean age 25.3 (range 1 2- 71) years), who were followed up for a mean of 12.02 years. Mutations in PTPN11 were identified in 35% of probands. Ten subjects died during the study interval; three of these deaths were secondary to heart failure associated with hypertrophic cardiomyopathy. Pulmonary stenosis affected 73 (65%) subjects; 42 (58%) required no intervention, nine underwent balloon pulmonary valvuloplasty (three requiring further intervention) and 22 surgical valvuloplasty (three requiring further intervention). Hypertrophic cardiomyopathy affected 21 (19%) patients, which had remitted in two cases, but one subject required cardiac transplant. No subjects died suddenly or had symptoms suggestive of arrhythmia. The mean final adult height was 167.4 cm in males and 152.7 cm in females. Feeding problems in infancy were identified as a predictor of future outcome. The mean age of speaking in two-word phrases was 26 months for those with no feeding difficulties, compared with 39 months for those with severe problems requiring nasogastric feeding. Attendance at a school for children with special needs for the same groups was 12.5% and 58%, respectively. A statement of special educational need had been issued in 44% overall; however, academic achievement was broadly similar to that of the general population. Implications: Although the morbidity for some patients with Noonan syndrome is low, early predictors of poorer outcome have been identified, which will help ascertain those most in need of intervention.
ACCESSION #
24168289

 

Related Articles

  • A novel mechanism associated with idiopathic ventricular fibrillation (IVF) mutations R1232W and T1620M in human cardiac sodium channels. Vilin, Yuriy Y.; Fujimoto, Esther; Ruben, Peter C. // Pflugers Archiv European Journal of Physiology;May2001, Vol. 442 Issue 2, p204 

    Two mutations associated with idiopathic ventricular fibrillation (IVF) are localized within extracellular loops between segments DIIIS1-S2 (R1232W) and DIVS3-S4 (T1620M) of the human cardiac sodium channel (hNaV1.5) α-subunit. We studied wild-type hNaV1.5 channels and hNaV1.5 channels with...

  • Hypertrophic cardiomyopathy: current understanding and treatment objectives. G S Soor // Journal of Clinical Pathology;Mar2009, Vol. 62 Issue 3, p226 

    The understanding of hypertrophic cardiomyopathy (HCM) has changed dramatically over the last few decades, and it is now understood to be caused by a mutation in one of several cardiac sarcomeric genes. Due to complications such as outflow tract obstruction, diastolic dysfunction, arrhythmias,...

  • Mutations in KCNA5 encoding the alfa-subunit of the K+ channel Kv1.5 cause sudden cardiac death.  // Cardiology in the Young;May2005 Supplement 2, Vol. 15 Issue S2, p46 

    This article focuses on a study related to the effects of a mutation in the gene KCNA5 on cardiac arrhythmia. 88 patients were screened for mutations in the coding region of KCNA5 using single strand conformation polymorphism analysis and DNA sequencing. In these patients no disease-causing...

  • Clinical aspects and physiopathology of Brugada syndrome: review of current concepts. Herbert, E.; Chahine, M. // Canadian Journal of Physiology & Pharmacology;Aug/Sep2006, Vol. 84 Issue 8/9, p795 

    Brugada syndrome (BS) is an inherited cardiac disorder characterized by typical electrocardiographic patterns of ST segment elevation in the precordial leads, right bundle branch block, fast polymorphic ventricular tachycardia in patients without any structural heart disease, and a high risk of...

  • Systolic Heart Failure in a Patient With Hypertrophic Obstructive Cardiomyopathy. Whitten, Shannon Etheridge // Critical Care Nurse;Oct2008, Vol. 28 Issue 5, p44 

    The article offers information on hypertrophic obstructive cardiomyopathy, a genetically transmitted disease. Complications of the disease include heart failure, atrial and ventricular arrhythmia and sudden cardiac death. Options for patients who do not respond to medication like percutaneous...

  • Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Mohler, Peter J.; Schott, Jean-Jacques; Gramolini, Anthony O.; Dilly, Keith W.; Guatimosim, Silvia; duBell, William H.; Song, Long-Sheng; Haurogné, Karine; Kyndt, Florence; Ali, Mervat E.; Rogers, Terry B.; Lederer, W. J.; Escande, Denis; Marec, Herve Le; Bennett, Vann // Nature;2/6/2003, Vol. 421 Issue 6923, p634 

    Mutations in ion channels involved in the generation and termination of action potentials constitute a family of molecular defects that underlie fatal cardiac arrhythmias in inherited long-QT syndrome. We report here that a loss-of-function (E1425G) mutation in ankyrin-B (also known as ankyrin...

  • Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy. Alcalde, Mireia; Campuzano, Oscar; Berne, Paola; García-Pavía, Pablo; Doltra, Ada; Arbelo, Elena; Sarquella-Brugada, Georgia; Iglesias, Anna; Alonso-Pulpon, Luis; Brugada, Josep; Brugada, Ramon // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a cardiac disease characterized by the presence of fibrofatty replacement of the right ventricular myocardium, which may cause ventricular arrhythmias and sudden cardiac death. Pathogenic mutations in several genes encoding...

  • ANGINA DRUG MAY GUARD AGAINST SUDDEN ARRHYTHMIAS.  // RN;Apr2008, Vol. 71 Issue 4, p22 

    The article discusses research on the electrophysiological effects of angina drug ranolazine, brand name Ranexa, on patients with long QT syndrome (LQTS), published in the web site Eurekalert.org. The author relates that approximately 1000 people die each year from LQTS, most of whom are...

  • Education: Rare diseases - Brugada syndrome.  // GP: General Practitioner;6/24/2013, p7 

    Dr Keith Barnard discusses the rare cardiac disorder, Brugada syndrome.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics